Pharmacotherapeutic group: ophthalmologicals, other antiallergics, ATC code: S01GX01.
Sodium cromoglicate stabilizes mast cell membranes, thereby preventing their degranulation and the release of mediators of allergic reaction and inflammation upon contact with an antigen. Through this mechanism, cromoglicate prevents both the release of preformed mediators (e.g., histamine, kinins), which mediate immediate type I allergic reactions, as well as mediators synthesized only after provocation (prostaglandins, leukotrienes), which mediate delayed type IV reactions.
Cromoglicate also prevents the activation of calcium channels. It blocks the calcium channel associated with the IgE receptor, thereby preventing calcium influx into the cell following IgE binding. This mechanism also inhibits mast cell degranulation and histamine release.
⚠️ Warnings
During treatment — and during allergic conjunctivitis in general — patients should not wear contact lenses. If, for exceptional reasons, the physician permits their use, the patient must remove the contact lenses before application of the product; lenses may be reinserted no sooner than 15 minutes after instillation.
